Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with R-CHOP for TP53-mutated DLBCL
NCT06158399Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Xiamen University. Started Nov 2023; status: recruiting.
02
Drugs
azacitidine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06158399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158399.